This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Pomerantz_LLP investigates...
Regulatory securities fraud investigation

Pomerantz_LLP investigates enGene_Therapeutics fraud

Analysis based on 8 articles · First reported May 19, 2026 · Last updated Jun 02, 2026

Sentiment
-70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the significant drop in enGene Therapeutics' stock price, reflecting investor concern over the disappointing clinical trial results. The investigation by Pomerantz LLP could lead to further financial repercussions for enGene Therapeutics and potentially impact investor confidence in the biotechnology sector.

Biotechnology Legal Services
Event Summary

Pomerantz LLP is investigating enGene Therapeutics for securities fraud and unlawful business practices following a drastic 80.56% drop in the company's stock price on May 7, 2026. This decline occurred after enGene Therapeutics announced updated interim results from its Phase 2 LEGEND trial for detalimogene voraplasmid, a drug for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company disclosed a 12-month duration of response of 25%, stating that 'durability outcomes to date are not what we hoped.' Pomerantz LLP is advising affected investors to contact them regarding a potential class action lawsuit.

Entities Involved
priv
enGene Therapeutics
enGene Therapeutics is facing a securities fraud investigation by Pomerantz LLP after its stock price plummeted due to disappointing clinical trial results for its drug detalimogene voraplasmid.
Importance 100.0 Sentiment -90.0
priv
Pomerantz LLP
Pomerantz LLP is investigating enGene Therapeutics for potential securities fraud and is advising investors to contact them regarding a class action lawsuit.
Importance 80.0 Sentiment 50.0
per
Danielle Peyton
Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the class action against enGene Therapeutics.
Importance 30.0 Sentiment 0.0
Relationships
Pomerantz LLP related ↔ Danielle Peyton
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.